TORONTO, Ontario and CAMBRIDGE, Massachusetts – Sept.1, 2021– ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Josh Mandel-Brehm to its Board of Directors with immediate effect.
“I am delighted to welcome Josh Mandel-Brehm as a member of the ProMIS Board of Directors at this time”, said Eugene Williams, Executive Chairman of ProMIS Neurosciences. “Josh has built a productive platform company in CAMP4, which experience is very relevant to ProMIS and our unique platform opportunity. Combined with his tremendous background in business development, capital formation, and strategy, we believe Josh will make significant contributions to the ProMIS Board.”
“I am very pleased to join the Board of Directors of ProMIS”, stated Josh Mandel-Brehm. “PMN310 has the potential to change the lives of many patients suffering from Alzheimer’s Disease and I am especially impressed by the technology platform and the team. ProMIS is well positioned to build a portfolio of next generation, differentiated antibody-based therapeutics in neurodegenerative and other mis-folded protein diseases, an area that I expect will be of increasing interest to investors and large pharma.”
Josh Mandel-Brehm is President & Chief Executive Officer of CAMP4 Therapeutics and holds a dual appointment as entrepreneur partner with Polaris Partners. He is also a co-founder and board member for Vico Therapeutics, an oligonucleotide-based RNA modulating Company focused on developing therapeutics for patients suffering from rare CNS disorders.
Mr. Mandel-Brehm previously held key business development and operations leadership roles at leading biotech companies. Most recently he served as part of the Business Development group at Biogen, where he led multiple strategic activities and corresponding transactions, which included expanding Biogen’s non-malignant hematology franchise, overseeing seminal investments to enter the ophthalmology field and advancing Biogen’s gene therapy strategy. Prior to Biogen, Mr. Mandel-Brehm held several roles of increasing responsibility at Genzyme as part of the business development group for the company’s rare disease business unit.
Mr. Mandel-Brehm earned a BA in Biology from Washington University in St. Louis and holds an MBA from the University of Michigan.
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform -ProMIS™ and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
For further information about ProMIS Neurosciences, please consult the Company’s website at: www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
Tel. 617 901-0785
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.